The Neuro’s Clinical Research Unit (CRU) evaluates the efficacy of new drugs and treatment regimens. Many patients come to it because they want to have access to the newest medications and diagnostic procedures. Since 1992, 140 trials have been conducted within the CRU, giving over 1000 patients suffering from multiple sclerosis, epilepsy, stroke, ALS or brain cancer access to new treatments. The CRU has access to the most advanced medical technology available today. The CRU conducts clinical trials sponsored by pharmaceutical companies or granting agencies such as the National Institutes of Health (NIH) in the USA. All clinical trials are approved by Health Canada (and the FDA if conducted in USA) and have passed a rigorous review by The Neuro's Research Ethics Board or the McGill Institutional Review Board. All experimental medications used in clinical trials have been tested for safety.
The CRU is dedicated to:
- Aiding the advancement of neuroscience through clinical research
- Participating in clinical trials to identify new or more effective treatments.
- Supplying study subjects with the best quality of care.
- Providing high quality data to sponsors and investigators.